Targeted treatments for immune dysregulation in inborn errors of immunity

Abstract

Primary immune regulatory disorders (PIRDs) constitute a subset of inborn errors of immunity and are characterized by lymphoproliferation, autoimmunity, malignancy, and infection. Unlike classical primary immune deficiencies, initial symptoms of PIRDs can manifest as autoimmunity such as cytopenias or enteropathy, which can often prove resistant to conventional treatments and occur years prior to the onset of infectious complications. Raising awareness about PIRDs among specialists and adopting a multidisciplinary approach is crucial for early diagnosis, intervention, and potential prevention of severe organ damage. Significant progress has been made in identifying several PIRDs, which has contributed to a more comprehensive comprehension of their underlying immunological mechanisms. This knowledge has paved the way for targeted therapies focusing on specific molecules, which tend to offer superior disease control compared to traditional immunosuppressants. This review, informed by the latest literature, explores prevalent PIRDs, detailing their clinical manifestations and recent advancements in treatment modalities.

Keywords

Primary immune deficiency / targeted therapies / immune dysregulation / inborn errors of immunity

References

[1] 2019 CIS annual meeting: Immune Deficiency & Dysregulation North American Conference. J Clin Immunol. 2019; 39: 1-151.

[2] Castagnoli R, Notarangelo LD. Updates on new monogenic inborn errors of immunity. Pediatr Allergy Immunol. 2020; 31: 57-9.

[3] Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022; 42: 1473-507.

[4] Costagliola G, Cappelli S, Consolini R. Autoimmunity in primary immunodeficiency disorders: an updated review on pathogenic and clinical implications. J Clin Med. 2021; 10: 4729.

[5] Amaya-Uribe L, Rojas M, Azizi G, Anaya JM, Gershwin ME. Primary immunodeficiency and autoimmunity: a comprehensive review. J Autoimmun. 2019; 99: 52-72.

[6] Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am. 2010; 24: 285-306.

[7] Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002; 168: 4620-7.

[8] Abubakar SD, Ihim SA, Farshchi A, Maleknia S, Abdullahi H, Sasaki T, et al. The role of TNF-α and anti-TNF-α agents in the immunopathogenesis and management of immune dysregulation in primary immunodeficiency diseases. Immunopharmacol Immunotoxicol. 2022; 44: 147-56.

[9] Aukrust P, Lien E, Kristoffersen AK, Müller F, Haug CJ, Espevik T, et al. Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency-possible immunologic and clinical consequences. Blood. 1996; 87: 674-81.

[10] Lin JH, Liebhaber M, Roberts RL, Dyer Z, Stiehm ER. Etanercept treatment of cutaneous granulomas in common variable immunodeficiency. J Allergy Clin Immunol. 2006; 117: 878-82.

[11] Smith KJ, Skelton H. Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-α receptor fusion protein. Br J Dermatol. 2001; 144: 597-600.

[12] Franxman TJ, Howe LE, Baker JR Jr. Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency. J Clin Immunol. 2014; 34: 820-7.

[13] Mitra A, Gooi J, Darling J, Newton-Bishop JA. Infliximab in the treatment of a child with cutaneous granulomas associated with ataxia telangiectasia. J Am Acad Dermatol. 2011; 65: 676-7.

[14] van Stigt AC, Dik WA, Kamphuis LSJ, Smits BM, van Montfrans JM, van Hagen PM, et al. What works when treating granulomatous disease in genetically undefined CVID? A systematic review. Front Immunol. 2020; 11: 606389.

[15] Woelke S, Valesky E, Bakhtiar S, Pommerening H, Pfeffermann LM, Schubert R, et al. Treatment of granulomas in patients with ataxia telangiectasia. Front Immunol. 2018; 9: 2000.

[16] Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum. 2012; 64: 908-13.

[17] Jacobelli S, André M, Alexandra JF, Dodé C, Papo T. Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford). 2007; 46: 1211-2.

[18] Nedjai B, Hitman GA, Quillinan N, Coughlan RJ, Church L, McDermott MF, et al. Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2009; 60: 619-25.

[19] ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015; 74: 1636-44.

[20] Akazawa Y, Takeshima F, Yajima H, Imanishi D, Kanda T, Matsushima K, et al. Infliximab therapy for Crohn’s-like disease in common variable immunodeficiency complicated by massive intestinal hemorrhage: a case report. BMC Res Notes. 2014; 7: 382.

[21] Chua I, Standish R, Lear S, Harbord M, Eren E, Raeiszadeh M, et al. Anti-tumour necrosis factor-α therapy for severe enteropathy in patients with common variable immunodeficiency (CVID). Clin Exp Immunol. 2007; 150: 306-11.

[22] Boschetti G, Sarfati M, Fabien N, Flourié B, Lachaux A, Nancey S, et al. Infliximab induces clinical resolution of sacroiliitis that coincides with increased circulating FOXP3⁺ T cells in a patient with IPEX syndrome . Joint Bone Spine. 2020; 87: 483-6.

[23] Ge T, Wang Y, Che Y, Xiao Y, Zhang T. Atypical late-onset immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome with intractable diarrhea: a case report. Front Pediatr. 2017; 5: 267.

[24] Horiuchi S, Ishiguro A, Nakagawa T, Shoji K, Nagai A, Arai K, et al. Girl with IPEX syndrome with low expression of Foxp3. Nihon Rinsho Meneki Gakkai Kaishi. 2012; 35: 526-32. Japanese.

[25] Jamee M, Hosseinzadeh S, Sharifinejad N, Zaki-Dizaji M, Matloubi M, Hasani M, et al. Comprehensive comparison between 222 CTLA-4 haploinsufficiency and 212 LRBA deficiency patients: a systematic review. Clin Exp Immunol. 2021; 205: 28-43.

[26] Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis. Clin Infect Dis. 2010; 51: 1429-34.

[27] Çakan M, Aktay Ayaz N, Erol Çipe F, Gül Karadağ Ş. Immunodeficiency-like phenotype, recurrent pulmonary manifestations, and persistent polyarthritis: Mevalonate kinase deficiency successfully treated with adalimumab. Arch Rheumatol. 2020; 35: 627-8.

[28] Bustamante-Ogando JC, Scheffler-Mendoza S, Yamazaki-Nakashimada MA, Saez-de-Ocariz M. IL-1 receptor antagonist defect (DIRA) in a pediatric patient, receiving adalimumab with good clinical response. Int J Dermatol. 2021; 60: 639-40.

[29] Di Gangi M, Amato G, Converso G, Benenati A, Leonetti C, Borella E, et al. Long-term efficacy of adalimumab in hyperimmunoglobulin D and periodic fever syndrome. Isr Med Assoc J. 2014; 16: 605-7.

[30] Li J, Shouval DS, Doty AL, Snapper SB, Glover SC. Increased mucosal IL-22 production of an IL-10RA mutation patient following Anakin treatment suggests further mechanism for mucosal healing. J Clin Immunol. 2017; 37: 104-7. Erratum in: J Clin Immunol. 2017; 37:108.

[31] Sharma A, Naidu G, Sharma V, Jha S, Dhooria A, Dhir V, et al. Deficiency of adenosine deaminase 2 in adults and children: experience from India. Arthritis Rheumatol. 2021; 73: 276-85.

[32] Demidowich AP, Freeman AF, Kuhns DB, Aksentijevich I, Gallin JI, Turner ML, et al. Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum. 2012; 64: 2022-7.

[33] Lu LY, Tang XY, Luo GJ, Tang MJ, Liu Y, Yu XJ. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome in a Chinese family: a case report and review of literature. World J Clin Cases. 2021; 9: 6393-402.

[34] Matsuda T, Kambe N, Takimoto-Ito R, Ueki Y, Nakamizo S, Saito MK, et al. Potential benefits of TNF targeting therapy in Blau syndrome, a NOD2-associated systemic autoinflammatory granulomatosis. Front Immunol. 2022; 13: 895765.

[35] Gerriets V, Goyal A, Khaddour K. Tumor necrosis factor inhibitors. Treasure Island (FL): StatPearls Publishing; 2024.

[36] Cohen Barak E, Kerner M, Rozenman D, Ziv M. Combination therapy of cyclosporine and anti-tumor necrosis factor α in psoriasis: a case series of 10 patients. Dermatol Ther. 2015; 28: 126-30.

[37] Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med. 2006; 355: 581-92.

[38] Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet. 2004; 364: 1779-85.

[39] Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol. 2006; 142: 1591-7.

[40] Maksimovic L, Stirnemann J, Caux F, Ravet N, Rouaghe S, Cuisset L, et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology (Oxford). 2008; 47: 309-10.

[41] Behrens EM, Kreiger PA, Cherian S, Cron RQ. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol. 2006; 33: 2081-4.

[42] Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2011; 50: 417-9.

[43] Wohlfarth P, Agis H, Gualdoni GA, Weber J, Staudinger T, Schellongowski P, et al. Interleukin 1 receptor antagonist anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically ill adult patients with hemophagocytic lymphohistiocytosis. J Intensive Care Med. 2019; 34: 723-31.

[44] Harrison SR, McGonagle D, Nizam S, Jarrett S, van der Hilst J, McDermott MF, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight. 2016; 1: e86336.

[45] Seger RA. Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med. 2010; 68: 334-40.

[46] Aeschlimann FA, Batu ED, Canna SW, Go E, Gül A, Hoffmann P, et al. A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Ann Rheum Dis. 2018; 77: 728-35.

[47] Gans MD, Wang H, Moura NS, Aksentijevich I, Rubinstein A. A20 haploinsufficiency presenting with a combined immunodeficiency. J Clin Immunol. 2020; 40: 1041-4.

[48] Selected abstracts from the 13^th annual meeting of the Clinical Immunology Society: 2022 annual meeting: Immune Deficiency and Dysregulation North American Conference . J Clin Immunol. 2022; 42: 1-115.

[49] Roy NBA, Zaal AI, Hall G, Wilkinson N, Proven M, McGowan S, et al. Majeed syndrome: description of a novel mutation and therapeutic response to bisphosphonates and IL-1 blockade with anakinra. Rheumatology (Oxford). 2020; 59: 448-51.

[50] Garg M, de Jesus AA, Chapelle D, Dancey P, Herzog R, Rivas-Chacon R, et al. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist. JCI Insight. 2017; 2: e94838.

[51] El Hasbani G, Jawad A, Uthman I. Update on the management of colchicine resistant familial Mediterranean fever (FMF). Orphanet J Rare Dis. 2019; 14: 224.

[52] Sopeña B, Araújo O, Freire M, Barrera-López L, Hernández-Rodríguez J. Efficacy of canakinumab in a patient with adult-onset glucocorticoid-resistant periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome. Mod Rheumatol Case Rep. 2023; 7: 276-9.

[53] Stojanov S, Lapidus S, Chitkara P, Feder H, Salazar JC, Fleisher TA, et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc Natl Acad Sci U S A. 2011; 108: 7148-53.

[54] Papa R, Penco F, Volpi S, Sutera D, Caorsi R, Gattorno M. Syndrome of undifferentiated recurrent fever (SURF): an emerging group of autoinflammatory recurrent fevers. J Clin Med. 2021; 10: 1963.

[55] Omenetti A, Carta S, Caorsi R, Finetti M, Marotto D, Lattanzi B, et al. Disease activity accounts for long-term efficacy of IL-1 blockers in pyogenic sterile arthritis pyoderma gangrenosum and severe acne syndrome. Rheumatology (Oxford). 2016; 55: 1325-35.

[56] Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis. 2006; 65: 1006-12.

[57] Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009; 36: 1118-25.

[58] Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016; 44: 275-81.

[59] Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998; 41: 2196-204.

[60] Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic A, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014; 134: 1293-300.

[61] Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020; 50: 5-14.

[62] Giancotta C, Colantoni N, Pacillo L, Santilli V, Amodio D, Manno EC, et al. Tailored treatments in inborn errors of immunity associated with atopy (IEIs-A) with skin involvement. Front Pediatr. 2023; 11: 1129249.

[63] Chiriaco M, Ursu GM, Amodio D, Cotugno N, Volpi S, Berardinelli F, et al. Radiosensitivity in patients affected by ARPC1B deficiency: a new disease trait? Front Immunol. 2022; 13: 919237.

[64] Consiglieri G, Ferrua F; San Raffaele Hospital Consortium; Aiuti A, Cicalese MP. A case of two adult brothers with Wiskott-Aldrich syndrome, one treated with gene therapy and one with HLA-identical hematopoietic stem cell transplantation. J Clin Immunol. 2022; 42: 421-5. Erratum in: J Clin Immunol. 2022; 42:426.

[65] Karpathiou G, Papoudou-Bai A, Ferrand E, Dumollard JM, Peoc’h M. STAT6: a review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology. Pathol Res Pract. 2021; 223: 153477.

[66] Lévy R, Béziat V, Barbieux C, Puel A, Bourrat E, Casanova JL, et al. Efficacy of dupilumab for controlling severe atopic dermatitis in a patient with hyper-IgE syndrome. J Clin Immunol. 2020; 40: 418-20.

[67] Maher MC, Hall EM, Horii KA. Generalized eczematous dermatitis and pruritus responsive to dupilumab in a patient with immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Pediatr Dermatol. 2021; 38: 1370-1.

[68] Murase C, Takeichi T, Taki T, Yoshikawa T, Suzuki A, Ogi T, et al. Successful dupilumab treatment for ichthyotic and atopic features of Netherton syndrome. J Dermatol Sci. 2021; 102: 126-9.

[69] Ollech A, Mashiah J, Lev A, Simon AJ, Somech R, Adam E, et al. Treatment options for DOCK8 deficiency-related severe dermatitis. J Dermatol. 2021; 48: 1386-93.

[70] Süßmuth K, Traupe H, Loser K, Ständer S, Kessel C, Wittkowski H, et al. Response to dupilumab in two children with Netherton syndrome: improvement of pruritus and scaling. J Eur Acad Dermatol Venereol. 2021; 35: e152-5.

[71] Steuer AB, Cohen DE. Treatment of Netherton syndrome with dupilumab. JAMA Dermatol. 2020; 156: 350-1.

[72] Moin A, Farhoudi A, Moin M, Pourpak Z, Bazargan N. Cutaneous manifestations of primary immunodeficiency diseases in children. Iran J Allergy Asthma Immunol. 2006; 5: 121-6.

[73] Olbrich P, Ortiz Aljaro P, Freeman AF. Eosinophilia associated with immune deficiency. J Allergy Clin Immunol Pract. 2022; 10: 1140-53.

[74] Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, et al. ; HES Mepolizumab study group. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020; 146: 1397-405.

[75] Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. ; EGPA Mepolizumab Study Team. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017; 376: 1921-32.

[76] Adatia A, Allen CJ, Wald J, Richards CD, Waserman S, Nair P. Benralizumab for prednisone-dependent eosinophilic asthma associated with novel STAT3 loss of function mutation. Chest. 2021; 159: e181-4.

[77] Sharma M, Leung D, Momenilandi M, Jones LCW, Pacillo L, James AE, et al. Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease. J Exp Med. 2023; 220: e20221755.

[78] Murakami M, Kamimura D, Hirano T. Pleiotropy and specificity: insights from the interleukin 6 family of cytokines. Immunity. 2019; 50: 812-31.

[79] Milner JD, Vogel TP, Forbes L, Ma CA, Stray-Pedersen A, Niemela JE, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015; 125: 591-9.

[80] Ma M, Mazumder S, Kwak H, Adams M, Gregory M. Case report: acute thrombotic microangiopathy in a patient with STING-associated vasculopathy with onset in infancy (SAVI). J Clin Immunol. 2020; 40: 1111-5.

[81] Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017; 13: 1972-88.

[82] Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011; 50: 552-62.

[83] Rello J, Rodriguez R, Jubert P, Alvarez B ; Study Group for Severe Community-Acquired Pneumonia. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Clin Infect Dis. 1996; 23: 723-8.

[84] Floss DM, Moll JM, Scheller J. IL-12 and IL-23-close relatives with structural homologies but distinct immunological functions. Cells. 2020; 9: 2184.

[85] Frare CP, Blumstein AJ, Paller AS, Pieretti L, Choate KA, Bowcock AM, et al. CARD14-associated papulosquamous eruption (CAPE) in pediatric patients: three additional cases and review of the literature . Pediatr Dermatol. 2021; 38: 1237-42.

[86] Volc S, Maier L, Gritsch A, Aichelburg MC, Volc-Platzer B. Successful treatment of Netherton syndrome with ustekinumab in a 15-year-old girl. Br J Dermatol. 2020; 183: 165-7.

[87] Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019; 16: 185-96.

[88] Kolukısa B, Barış S. Primary immune regulatory disorders and targeted therapies. Turk J Haematol. 2021; 38: 1-14.

[89] Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood. 2019; 134: 1783-6.

[90] Marsh RA, Allen CE, McClain KL, Weinstein JL, Kanter J, Skiles J, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013; 60: 101-9.

[91] Matson EM, Abyazi ML, Bell KA, Hayes KM, Maglione PJ. B cell dysregulation in common variable immunodeficiency interstitial lung disease. Front Immunol. 2021; 11: 622114.

[92] Verbsky JW, Hintermeyer MK, Simpson PM, Feng M, Barbeau J, Rao N, et al. Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency. J Allergy Clin Immunol. 2021; 147: 704-12.e17.

[93] Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother. 2018; 14: 2820-41.

[94] Comberiati P, Costagliola G, Carli N, Legitimo A, D’Elios S, Consolini R, et al. Refractory chronic spontaneous urticaria treated with omalizumab in an adolescent with common variable immunodeficiency. Front Immunol. 2019; 10: 1700.

[95] El-Qutob D. Off-label uses of omalizumab. Clin Rev Allergy Immunol. 2016; 50: 84-96.

[96] Gomes N, Miranda J, Lopes S, Carneiro-Leão L, Torres Costa J, Baudrier T, et al. Omalizumab in the treatment of hyper-IgE syndrome: 2 case reports. J Investig Allergol Clin Immunol. 2020; 30: 191-2.

[97] Lan J, Zhang Y, Song M, Cai S, Luo H, OuYang R, et al. Omalizumab for STAT3 hyper-IgE syndromes in adulthood: a case report and literature review. Front Med (Lausanne). 2022; 9: 835257.

[98] Ozen A, Kasap N, Vujkovic-Cvijin I, Apps R, Cheung F, Karakoc-Aydiner E, et al. Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease. Nat Immunol. 2021; 22: 128-39.

[99] Latuszek A, Liu Y, Olsen O, Foster R, Cao M, Lovric I, et al. Inhibition of complement pathway activation with pozelimab, a fully human antibody to complement component C5. PLoS One. 2020; 15: e0231892.

[100] Cataldi M, Cavaccini A. Eculizumab☆. In: Reference module in biomedical sciences. Elsevier; 2016.

[101] Powers JP, Dairaghi DJ, Jaen JC. Chapter 11 - Advances in the discovery of C5a receptor antagonists. In: Macor JE, editor. Annual reports in medicinal chemistry. Academic Press; 2011. pp. 171-86.

[102] Kiykim A, Ogulur I, Dursun E, Charbonnier LM, Nain E, Cekic S, et al. Abatacept as a long-term targeted therapy for LRBA deficiency. J Allergy Clin Immunol Pract. 2019; 7: 2790-800.e15.

[103] Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014; 345: 1623-7.

[104] Westermann-Clark E, Ballow M, Walter JE. The new quest in CTLA-4 insufficiency: How to immune modulate effectively? J Allergy Clin Immunol. 2022; 149: 543-6.

[105] Yang L, Xue X, Chen X, Wu J, Yang X, Xu L, et al. Abatacept is effective in Chinese patients with LRBA and CTLA4 deficiency. Genes Dis. 2020; 8: 662- 8.

[106] Liu M, Yu Y, Hu S. A review on applications of abatacept in systemic rheumatic diseases. Int Immunopharmacol. 2021; 96: 107612.

[107] Deyà-Martínez A, Rivière JG, Roxo-Junior P, Ramakers J, Bloomfield M, Guisado Hernandez P, et al. Impact of JAK inhibitors in pediatric patients with STAT1 gain of function (GOF) mutations-10 children and review of the literature. J Clin Immunol. 2022; 42: 1071-82.

[108] Leiding JW, Vogel TP, Santarlas VGJ, Mhaskar R, Smith MR, Carisey A, et al.; STAT3 GOF Working Group members; Seppänen MRJ, Torgerson TR, Sogkas G, Ehl S, Tangye SG, Cooper MA, et al. Monogenic early-onset lymphoproliferation and autoimmunity: natural history of STAT3 gain-of-function syndrome. J Allergy Clin Immunol. 2023; 151: 1081-95.

[109] Eisenberg R, Gans MD, Leahy TR, Gothe F, Perry C, Raffeld M, et al. JAK inhibition in early-onset somatic, nonclonal STAT5B gain-of-function disease. J Allergy Clin Immunol Pract. 2021; 9: 1008-10.e2.

[110] Biggs CM, Cordeiro-Santanach A, Prykhozhij SV, Deveau AP, Lin Y, Del Bel KL, et al. Human JAK1 gain of function causes dysregulated myelopoeisis and severe allergic inflammation. JCI Insight. 2022; 7: e150849.

[111] Hoisnard L, Lebrun-Vignes B, Maury S, Mahevas M, El Karoui K, Roy L, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022; 12: 7140.

[112] Barsalou J, Blincoe A, Fernandez I, Dal-Soglio D, Marchitto L, Selleri S, et al. Rapamycin as an adjunctive therapy for NLRC4 associated macrophage activation syndrome. Front Immunol. 2018; 9: 2162.

[113] Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. J Allergy Clin Immunol. 2018; 142: 1932-46.

[114] Maccari ME, Abolhassani H, Aghamohammadi A, Aiuti A, Aleinikova O, Bangs C, et al. Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. Front Immunol. 2018; 9: 543.

[115] Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009; 145: 101-6.

[116] López-Nevado M, González-Granado LI, Ruiz-García R, Pleguezuelo D, Cabrera-Marante O, Salmón N, et al. Primary immune regulatory disorders with an autoimmune lymphoproliferative syndrome-like phenotype: immunologic evaluation, early diagnosis and management. Front Immunol. 2021; 12: 671755.

[117] Rao VK, Webster S, Šedivá A, Plebani A, Schuetz C, Shcherbina A, et al. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome. Blood. 2023; 141: 971-83.

[118] Rao VK, Webster S, Dalm VASH, Šedivá A, van Hagen PM, Holland S, et al. Effective “activated PI3Kδ syndrome”-targeted therapy with the PI3Kδ inhibitor leniolisib. Blood. 2017; 130: 2307-16.

[119] Rao VK, Kulm E, Šedivá A, Plebani A, Schuetz C, Shcherbina A, et al. Interim analysis: open-label extension study of leniolisib for patients with APDS. J Allergy Clin Immunol. 2024; 153: 265-74.e9.

[120] Silva SD, Rajadhyaksha SB, Singh M. Immune dysregulation in MDS: the role of cytokines and immune cells. In: Fuchs O, editor. Recent developments in myelodysplastic syndromes. Rijeka: IntechOpen; 2019.

[121] Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014; 14: 36-49.

[122] Errante PR, Frazão JB, Condino-Neto A. The use of interferon-gamma therapy in chronic granulomatous disease. Recent Pat Antiinfect Drug Discov. 2008; 3: 225-30.

[123] International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med. 1991; 324: 509-16.

[124] Delmonte OM, Castagnoli R, Calzoni E, Notarangelo LD. Inborn errors of immunity with immune dysregulation: from bench to bedside. Front Pediatr. 2019; 7: 353.